PMID- 28190794
OWN - NLM
STAT- MEDLINE
DCOM- 20170502
LR  - 20170502
IS  - 1349-3299 (Electronic)
IS  - 1349-2365 (Linking)
VI  - 58
IP  - 2
DP  - 2017 Apr 6
TI  - A Randomized Comparative Study on the Efficacy of Intracoronary Infusion of 
      Autologous Bone Marrow Mononuclear Cells and Mesenchymal Stem Cells in Patients 
      With Dilated Cardiomyopathy.
PG  - 238-244
LID - 10.1536/ihj.16-328 [doi]
AB  - Stem cell therapy has shown therapeutic benefit in dilated cardiomyopathy (DCM), 
      but doubt remains about the most appropriate stem cell subpopulation. The current 
      study compared the efficacy of intracoronary administration of bone marrow 
      mononuclear cells (BMMC) or mesenchymal stem cells (BMSC) in patients with 
      DCM.Fifty-three patients with DCM and reduced (< 40%) left ventricular ejection 
      fraction (LVEF), were randomized to intracoronary infusion of BMMC (BMMC group, n 
      = 16) or BMSC (BMSC group, n = 17) or equal volume normal saline (CTRL group, n = 
      20). LVEF, New York Heart Association (NYHA) class, left ventricular 
      end-diastolic diameter (LVEDd), and myocardial perfusion were assessed at 
      baseline and at 3-month and 12-month follow-ups. Major adverse cardiovascular 
      events (MACE) were also recorded.At the 3-month follow-up, LVEF, NYHA class, and 
      myocardial perfusion had improved significantly in the BMSC group (P = 0.004, 
      0.020 and 0.019, respectively) along with significant changes in LVEF and NYHA 
      class in the BMMC group compared with CTRL (P = 0.042 and 0.047, respectively), 
      however, LVEDd remained unchanged. In comparison with CTRL, LVEF, NYHA class, and 
      myocardial perfusion improved significantly in the BMSC group at the 12-month 
      follow-up (P = 0.005, 0.050 and 0.038 respectively), but not in the BMMC group (P 
      > 0.05). There were no significant differences between the transplantation groups 
      during follow-up (P > 0.05). There were no differences in MACE among the 3 groups 
      (P = 0.817).Intracoronary bone marrow stem cell transplantation in DCM is safe 
      and effective, while BMSC and BMMC infusion possess comparable effectiveness.
FAU - Xiao, Wentao
AU  - Xiao W
AD  - Department of Cardiology, Henan Cardiovascular Hospital, Zhengzhou University 
      People's Hospital.
FAU - Guo, Suping
AU  - Guo S
FAU - Gao, Chuanyu
AU  - Gao C
FAU - Dai, Guoyou
AU  - Dai G
FAU - Gao, Yongjv
AU  - Gao Y
FAU - Li, Muwei
AU  - Li M
FAU - Wang, Xianpei
AU  - Wang X
FAU - Hu, Dayi
AU  - Hu D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20170213
PL  - Japan
TA  - Int Heart J
JT  - International heart journal
JID - 101244240
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Bone Marrow Transplantation
MH  - Cardiomyopathy, Dilated/*therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - *Mesenchymal Stem Cell Transplantation
MH  - Middle Aged
MH  - Stroke Volume
MH  - Transplantation, Autologous
MH  - Treatment Outcome
EDAT- 2017/02/14 06:00
MHDA- 2017/05/04 06:00
CRDT- 2017/02/14 06:00
PHST- 2017/02/14 06:00 [pubmed]
PHST- 2017/05/04 06:00 [medline]
PHST- 2017/02/14 06:00 [entrez]
AID - 10.1536/ihj.16-328 [doi]
PST - ppublish
SO  - Int Heart J. 2017 Apr 6;58(2):238-244. doi: 10.1536/ihj.16-328. Epub 2017 Feb 13.